Teva Pharmaceutical Industries (TEVA) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic transformation and growth pillars

• Executed a multi-phase strategy to pivot from generics to biopharma, achieving 11 consecutive quarters of growth since 2023 and targeting a full transition by 2030.

• Four pillars: growth engines, innovation, generics powerhouse, and business focus, with strong progress in each.

• Capital allocation and portfolio transformation have driven improved financials, including revenue, gross margin, and free cash flow, with a focus on shareholder returns.

• Sustained growth is expected from 2025 onward, with acceleration through 2027 and a long-term strategy targeting a 20-year horizon.

• Transition aims for gross margins above 60% and mid-single digit revenue growth.

Innovative product and pipeline development

• Doubled innovative business revenue in three years, with plans to continue doubling every two years and surpass $5B in innovative sales by 2030.

• Key products Austedo, Uzedy, and Ajovy have exceeded expectations, with combined peak sales potential exceeding $5B by 2030.

• Uzedy and upcoming Olanzapine are building a leading schizophrenia franchise, targeting $1.5–$2 billion in sales.

• Pipeline includes late-stage assets like Duvakitug, Anle138b, emrusolmin, and anti-IL-15, each with billion-dollar peak sales potential and first- or best-in-class potential.

• Anti-IL-15 programs for celiac and vitiligo address significant unmet needs, with first-in-class potential and fast-track designations.

Financial outlook and operational performance

• 2025 revenue outlook is $16.8B–$17.0B, with operating profit margin of 26.2%–27.1% and adjusted EBITDA of $4.8B–$5.0B.

• Free cash flow expected at $1.6B–$1.9B in 2025, with net leverage targeted at ~2.5x.

• Revenue for the current year is at the lower end of guidance, but operating margin, EBITDA, EPS, and free cash flow are at or above mid to high ranges.

• Despite losing $1.1 billion in generic Revlimid revenue in 2026, EBITDA, operating margin, and free cash flow are expected to grow, with operating margin projected to reach 30% by 2027 and $700 million in operational synergies realized.

• Transformation programs are expected to deliver cumulative savings of $700M by 2030.